Yi Fang Bio won the case of Mirati's technical secrets in the first instance.
Release time:
2024-09-30 17:42
Source:
On September 29, Yipang Biology issued a notice announcing that the company had received the "Civil Judgment" (Case No.:(2022) Shanghai 73 Zhimin Chu No. 1130) issued by the Shanghai Intellectual Property Court, regarding Mirati Medical (Mirati Therapeutics, hereinafter referred to as "Milati Company" or "Plaintiff") sued the company, the company's wholly-owned subsidiary, the U.S. interested party, and the company's director XING DAI (Daixing) for infringement of Milati Company and Yare Biotechnology Secrets. The court's first-instance judgment rejected all the plaintiff's claims.
In November 2022, Milati filed a lawsuit with the Shanghai Intellectual Property Court, claiming that Yifan Bio and its wholly-owned subsidiary, American Yifan and Company Director XING DAI (Generation Star), infringed on the technical secrets of Milati and Yare. Milati Company requested the court to order the above-mentioned defendant to stop the infringement, requested the court to confirm that the relevant patent right/patent application right belongs to Milati Company and Yalei Company, and requested the company, the U.S. interested party and XING DAI (Daixing) to jointly compensate Milati Company for economic losses and reasonable expenses totaling RMB 99 million yuan.
On August 3, 2023, November 16, 2023, March 14, 2024 and July 25, 2024, the court held a pretrial meeting on the case; on July 25, 2024, the case was heard in private.
On September 29, 2024, Yipang Bio received the "Civil Judgment" issued by the Shanghai Intellectual Property Court. The judgment was as follows: all claims of the plaintiff Milati Company in this case were rejected. The acceptance fee for this case is 536,800 yuan, which shall be borne by the plaintiff Milati Company.